Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements

Jain, Nidhi; Nagaich, Upendra; Pandey, Manisha; Chellappan, Dinesh Kumar; Dua, Kamal

doi:10.1007/s13167-022-00304-2

Cited by 5 publications

(2 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scholars have increasingly stressed the manifold ways in which AI systems can contribute to this paradigm shift in digital health. To previous samples of AI systems for diagnostics and prevention, precision medicine and medical research, clinical decision making and mobile health, healthcare management and service delivery, we may add work on the applicability of predictive diagnostics for the development of 3P-Medicine for clinical application [ 57 ]; AI supported patient self-care systems in chronic heart failure [ 58 ]; non-invasive diagnostic tools in coronary artery disease [ 59 ]; mass spectrometry-based technologies [ 60 ]; predictive diagnostics of dementia [ 61 ]; different stages of cellulite [ 62 ], and so forth.…”

Section: A World Of Affordancesmentioning

confidence: 99%

The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations

Pagallo,

O’Sullivan,

Nevejans

et al. 2023

Health Technol.

View full text Add to dashboard Cite

Purpose This contribution explores the underuse of artificial intelligence (AI) in the health sector, what this means for practice, and how much the underuse can cost. Attention is drawn to the relevance of an issue that the European Parliament has outlined as a "major threat" in 2020. At its heart is the risk that research and development on trusted AI systems for medicine and digital health will pile up in lab centers without generating further practical relevance. Our analysis highlights why researchers, practitioners and especially policymakers, should pay attention to this phenomenon. Methods The paper examines the ways in which governments and public agencies are addressing the underuse of AI. As governments and international organizations often acknowledge the limitations of their own initiatives, the contribution explores the causes of the current issues and suggests ways to improve initiatives for digital health. Results Recommendations address the development of standards, models of regulatory governance, assessment of the opportunity costs of underuse of technology, and the urgency of the problem. Conclusions The exponential pace of AI advances and innovations makes the risks of underuse of AI increasingly threatening. Graphical Abstract

show abstract

Section: A World Of Affordancesmentioning

confidence: 99%

The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations

Pagallo,

O’Sullivan,

Nevejans

et al. 2023

Health Technol.

View full text Add to dashboard Cite

show abstract

“…This can be illustrated by epidemics of non-communicable disorders demonstrating over a half of billion patients diagnosed with the diabetes mellitus and co-morbidities [ 2 ], breast cancer as the leading malignancy in female subpopulations [ 3 ], prostate cancer with the disease management costs annually increasing more rapidly than for any other cancer type [ 4 ] and alarming statistics of neurodegenerative disorders worldwide [ 5 ] . Since 2009, European Association for Predictive, Preventive and Personalised Medicine (EPMA, Brussels, www.epmanet.eu ) promotes the paradigm change from reactive approach to predictive, preventive, and personalized medicine (PPPM/3PM) to reverse currently observed unfavourable trends, to protect individuals in sub-optimal health conditions from the health-to-disease transition, to increase life-quality of the affected patient cohorts improving, therefore, ethical standards and cost-efficacy of healthcare to great benefits of the society at large [ 6 – 8 ].…”

Section: Preamblementioning

confidence: 99%

Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

et al. 2023

View full text Add to dashboard Cite

Since 2009, the European Association for Predictive, Preventive and Personalised Medicine (EPMA, Brussels) promotes the paradigm change from reactive approach to predictive, preventive, and personalized medicine (PPPM/3PM) to protect individuals in sub-optimal health conditions from the health-to-disease transition, to increase life-quality of the affected patient cohorts improving, therefore, ethical standards and cost-efficacy of healthcare to great benefits of the society at large. The gene-editing technology utilizing CRISPR/Cas gene-editing approach has demonstrated its enormous value as a powerful tool in a broad spectrum of bio/medical research areas. Further, CRISPR/Cas gene-editing system is considered applicable to primary and secondary healthcare, in order to prevent disease spread and to treat clinically manifested disorders, involving diagnostics of SARS-Cov-2 infection and experimental treatment of COVID-19. Although the principle of the proposed gene editing is simple and elegant, there are a lot of technological challenges and ethical considerations to be solved prior to its broadly scaled clinical implementation. This article highlights technological innovation beyond the state of the art, exemplifies current achievements, discusses unsolved technological and ethical problems, and provides clinically relevant outlook in the framework of 3PM.

show abstract

Trends and perception towards collection and preparation of human biological specimens for contaminant analysis

Arain,

Balal,

Soylak

2024

Reference Module in Chemistry, Molecular Sciences and Chemical Engineering

View full text Add to dashboard Cite

Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements

Cited by 5 publications

References 118 publications

The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations

The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations

Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

Trends and perception towards collection and preparation of human biological specimens for contaminant analysis

Contact Info

Product

Resources

About